(VIANEWS) – AMSC (AMSC.OL), SATS (SATS.OL), VISTIN PHARMA (VISTN.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. AMSC (AMSC.OL)
1395% sales growth and 8.21% return on equity
AMSC ASA, through its subsidiaries, invests in maritime assets and companies in the United States. It operates one international subsea construction vessel. The company was formerly known as American Shipping Company ASA and changed its name to AMSC ASA in October 2022. AMSC ASA was incorporated in 2005 and is headquartered in Lysaker, Norway.
Earnings Per Share
As for profitability, AMSC has a trailing twelve months EPS of kr-0.72.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.21%.
More news about AMSC.
2. SATS (SATS.OL)
6.6% sales growth and 24.17% return on equity
Sats ASA provides fitness and training services in Norway, Sweden, Denmark, and Finland. It offers sportswear, fitness gear, bars, and energy drinks. The company operates fitness clubs under the SATS, ELIXIA, Fresh Fitness, and SATSYoga brand names. Sats ASA was founded in 1995 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, SATS has a trailing twelve months EPS of kr1.16.
PE Ratio
SATS has a trailing twelve months price to earnings ratio of 14.4. Meaning, the purchaser of the share is investing kr14.4 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.17%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.7%, now sitting on 4.83B for the twelve trailing months.
Sales Growth
SATS’s sales growth for the next quarter is 6.6%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 10.9% and 146.7%, respectively.
More news about SATS.
3. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 19.84% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.27.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 17.32. Meaning, the purchaser of the share is investing kr17.32 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.84%.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the current quarter and 6.6% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 2.9%, now sitting on 441.27M for the twelve trailing months.
More news about VISTIN PHARMA.
